{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:09:18Z","timestamp":1778198958207,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-09034-3","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:57:25Z","timestamp":1763992645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters"],"prefix":"10.1038","volume":"8","author":[{"given":"N\u00faria","family":"Pedre\u00f1o-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferran","family":"Tarr\u00e9s-Freixas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-2765","authenticated-orcid":false,"given":"Carla","family":"Usai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-5700","authenticated-orcid":false,"given":"Dalia","family":"Ra\u00efch-Regu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Benet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erola","family":"Ainsua-Enrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julieta","family":"Carabelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-8920","authenticated-orcid":false,"given":"Edwards","family":"Pradenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"\u00c1vila-Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Cantero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f2nica","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6944-3462","authenticated-orcid":false,"given":"Maria Luisa","family":"Rodr\u00edguez de la Concepci\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Matilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Revollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Abad-Capa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-407X","authenticated-orcid":false,"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Mateu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3326-151X","authenticated-orcid":false,"given":"Marta","family":"Massanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1039-1821","authenticated-orcid":false,"given":"Nuria","family":"Izquierdo-Useros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-0217","authenticated-orcid":false,"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-4598","authenticated-orcid":false,"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1539-7261","authenticated-orcid":false,"given":"Joaquim","family":"Segal\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7484-444X","authenticated-orcid":false,"given":"J\u00falia","family":"Vergara-Alert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-5948","authenticated-orcid":false,"given":"Jorge","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"9034_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.medj.2021.01.005","volume":"2","author":"E Pradenas","year":"2021","unstructured":"Pradenas, E. et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med. 2, 313\u2013320.e4 (2021).","journal-title":"Med"},{"key":"9034_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"Q-X Long","year":"2020","unstructured":"Long, Q.-X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020).","journal-title":"Nat. Med."},{"key":"9034_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41423-020-0474-z","volume":"17","author":"H Ma","year":"2020","unstructured":"Ma, H. et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol. Immunol. 17, 773\u2013775 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"9034_CR4","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.xcrm.2020.100040","volume":"1","author":"MS Suthar","year":"2020","unstructured":"Suthar, M. S. et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep. Med. 1, 100040 (2020).","journal-title":"Cell Rep. Med."},{"key":"9034_CR5","doi-asserted-by":"crossref","unstructured":"Amellal, H. et al. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: a prospective longitudinal study. PLoS ONE 18 (2023).","DOI":"10.1371\/journal.pone.0288557"},{"key":"9034_CR6","doi-asserted-by":"crossref","unstructured":"Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol. 5 (2020).","DOI":"10.1126\/sciimmunol.abe5511"},{"key":"9034_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.abe0240","volume":"5","author":"K R\u00f6ltgen","year":"2020","unstructured":"R\u00f6ltgen, K. et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci. Immunol. 5, 1\u201320 (2020).","journal-title":"Sci. Immunol."},{"key":"9034_CR8","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41590-022-01248-5","volume":"23","author":"H Qi","year":"2022","unstructured":"Qi, H., Liu, B., Wang, X. & Zhang, L. The humoral response and antibodies against SARS-CoV-2 infection. Nat. Immunol. 23, 1008\u20131020 (2022).","journal-title":"Nat. Immunol."},{"key":"9034_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/22221751.2020.1762515","volume":"9","author":"B Sun","year":"2020","unstructured":"Sun, B. et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg. Microbes Infect. 9, 940\u2013948 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"9034_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81862-9","volume":"11","author":"B Trinit\u00e9","year":"2021","unstructured":"Trinit\u00e9, B. et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci. Rep. 11, 2608 (2021).","journal-title":"Sci. Rep."},{"key":"9034_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430\u2013436 (2020).","journal-title":"Nature"},{"key":"9034_CR12","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323, 2052\u20132059 (2020).","journal-title":"JAMA"},{"key":"9034_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","volume":"53","author":"C Atyeo","year":"2020","unstructured":"Atyeo, C. et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity 53, 524\u2013532.e4 (2020).","journal-title":"Immunity"},{"key":"9034_CR14","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","volume":"183","author":"T Zohar","year":"2020","unstructured":"Zohar, T. et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell 183, 1508\u20131519.e12 (2020).","journal-title":"Cell"},{"key":"9034_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036\u20131045.e9 (2020).","journal-title":"Cell"},{"key":"9034_CR16","first-page":"1419","volume":"182","author":"J Schulte-Schrepping","year":"2020","unstructured":"Schulte-Schrepping, J. et al. Severe COVID-19 is marked by a dysregulated myeloid. Cell Compartment. Cell 182, 1419\u20131440.e23 (2020).","journal-title":"Cell Compartment. Cell"},{"key":"9034_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012.e19 (2020).","journal-title":"Cell"},{"key":"9034_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","volume":"584","author":"C Lucas","year":"2020","unstructured":"Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463\u2013469 (2020).","journal-title":"Nature"},{"key":"9034_CR19","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.immuni.2021.05.006","volume":"54","author":"Q Lu","year":"2021","unstructured":"Lu, Q. et al. SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. Immunity 54, 1304\u20131319.e9 (2021).","journal-title":"Immunity"},{"key":"9034_CR20","unstructured":"Veras, F. P. et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 217 (2020)."},{"key":"9034_CR21","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.immuni.2021.09.002","volume":"54","author":"B Kr\u00e4mer","year":"2021","unstructured":"Kr\u00e4mer, B. et al. Early IFN-\u03b1 signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity 54, 2650\u20132669.e14 (2021).","journal-title":"Immunity"},{"key":"9034_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.01753-18","volume":"9","author":"LE Gralinski","year":"2018","unstructured":"Gralinski, L. E. et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 9, 1\u201315 (2018).","journal-title":"mBio"},{"key":"9034_CR23","doi-asserted-by":"publisher","first-page":"25018","DOI":"10.1073\/pnas.2010540117","volume":"117","author":"JC Holter","year":"2020","unstructured":"Holter, J. C. et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl Acad. Sci. USA 117, 25018\u201325025 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9034_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","volume":"588","author":"J Carvelli","year":"2020","unstructured":"Carvelli, J. et al. Association of COVID-19 inflammation with activation of the C5a\u2013C5aR1 axis. Nature 588, 146\u2013150 (2020).","journal-title":"Nature"},{"key":"9034_CR25","doi-asserted-by":"crossref","unstructured":"Chen, S. T. et al. A shift in lung macrophage composition is associated with COVID-19 severity and recovery. Sci. Transl. Med. 14 (2022).","DOI":"10.1126\/scitranslmed.abn5168"},{"key":"9034_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","volume":"606","author":"E Sefik","year":"2022","unstructured":"Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585\u2013593 (2022).","journal-title":"Nature"},{"key":"9034_CR27","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/s41590-023-01560-8","volume":"24","author":"MJ Lee","year":"2023","unstructured":"Lee, M. J. & Blish, C. A. Defining the role of natural killer cells in COVID-19. Nat. Immunol. 24, 1628\u20131638 (2023).","journal-title":"Nat. Immunol."},{"key":"9034_CR28","doi-asserted-by":"crossref","unstructured":"Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. JCI Insight 5 (2020).","DOI":"10.1172\/jci.insight.138999"},{"key":"9034_CR29","doi-asserted-by":"crossref","unstructured":"LaSalle, T. J. et al. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients. Cell Rep. Med. 3 (2022).","DOI":"10.1016\/j.xcrm.2022.100779"},{"key":"9034_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","volume":"6","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target Ther. 6, 255 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"9034_CR31","doi-asserted-by":"crossref","unstructured":"Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4 (2019).","DOI":"10.1172\/jci.insight.123158"},{"key":"9034_CR32","unstructured":"Larsen, M. D. et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science 371 (2021)."},{"key":"9034_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.abf8654","volume":"13","author":"W Hoepel","year":"2021","unstructured":"Hoepel, W. et al. High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci. Transl. Med. 13, 1\u201317 (2021).","journal-title":"Sci. Transl. Med."},{"key":"9034_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41590-020-00828-7","volume":"22","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty, S. et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat. Immunol. 22, 67\u201373 (2021).","journal-title":"Nat. Immunol."},{"key":"9034_CR35","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.1002\/jmv.27058","volume":"93","author":"FN Zervou","year":"2021","unstructured":"Zervou, F. N. et al. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J. Med Virol. 93, 5409\u20135415 (2021).","journal-title":"J. Med Virol."},{"key":"9034_CR36","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1126\/scitranslmed.abd2223","volume":"13","author":"D Sterlin","year":"2021","unstructured":"Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, 2223 (2021).","journal-title":"Sci. Transl. Med"},{"key":"9034_CR37","doi-asserted-by":"crossref","unstructured":"Stacey, H. D. et al. IgA potentiates NETosis in response to viral infection. Proc. Natl Acad. Sci. USA 118 (2021).","DOI":"10.1073\/pnas.2101497118"},{"key":"9034_CR38","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1126\/science.abe3354","volume":"370","author":"MA Tortorici","year":"2020","unstructured":"Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950\u2013957 (2020).","journal-title":"Science"},{"key":"9034_CR39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41577-020-0359-5","volume":"20","author":"T Zohar","year":"2020","unstructured":"Zohar, T. & Alter, G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat. Rev. Immunol. 20, 392\u2013394 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"9034_CR40","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"9034_CR41","doi-asserted-by":"publisher","first-page":"12039","DOI":"10.1128\/JVI.01650-12","volume":"86","author":"MD Alpert","year":"2012","unstructured":"Alpert, M. D. et al. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J. Virol. 86, 12039\u201312052 (2012).","journal-title":"J. Virol."},{"key":"9034_CR42","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","volume":"383","author":"DA Berlin","year":"2020","unstructured":"Berlin, D. A., Gulick, R. M. & Martinez, F. J. Severe Covid-19. N. Engl. J. Med. 383, 2451\u20132460 (2020).","journal-title":"N. Engl. J. Med."},{"key":"9034_CR43","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.  Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"9034_CR44","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 130, 2620\u20132629 (2020).","journal-title":"J. Clin. Investig."},{"key":"9034_CR45","doi-asserted-by":"crossref","unstructured":"Kuri-Cervantes, L. et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. 5 (2020).","DOI":"10.1126\/sciimmunol.abd7114"},{"key":"9034_CR46","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/cid\/ciaa489","volume":"71","author":"J Qu","year":"2020","unstructured":"Qu, J. et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71, 2255\u20132258 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"9034_CR47","doi-asserted-by":"publisher","first-page":"100523","DOI":"10.1016\/j.xcrm.2022.100523","volume":"3","author":"E Pradenas","year":"2022","unstructured":"Pradenas, E. et al. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Rep. Med. 3, 100523 (2022).","journal-title":"Cell Rep. Med."},{"key":"9034_CR48","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/scitranslmed.abf1555","volume":"13","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, 1555 (2021).","journal-title":"Sci. Transl. Med."},{"key":"9034_CR49","doi-asserted-by":"crossref","unstructured":"Fr\u00f6berg, J. et al. SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms. Nat. Commun. 12, (2021).","DOI":"10.1038\/s41467-021-25949-x"},{"key":"9034_CR50","doi-asserted-by":"crossref","unstructured":"Planchais, C. et al. Potent human broadly SARS-CoV-2\u2013neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. J. Exp. Med. 219 (2022).","DOI":"10.1101\/2022.04.01.486719"},{"key":"9034_CR51","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-022-04702-4","volume":"606","author":"C Junqueira","year":"2022","unstructured":"Junqueira, C. et al. Fc\u03b3R-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 606, 576\u2013584 (2022).","journal-title":"Nature"},{"key":"9034_CR52","first-page":"143","volume":"183","author":"N Kaneko","year":"2020","unstructured":"Kaneko, N. et al. Loss of Bcl-6-expressing T follicular helper. Cells Germinal Cent. COVID-19. Cell 183, 143\u2013157.e13 (2020).","journal-title":"Cells Germinal Cent. COVID-19. Cell"},{"key":"9034_CR53","doi-asserted-by":"crossref","unstructured":"Andreano, E. & Rappuoli, R. Immunodominant antibody germlines in COVID-19. J. Exp. Med. 218 (2021).","DOI":"10.1084\/jem.20210281"},{"key":"9034_CR54","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","volume":"21","author":"MC Woodruff","year":"2020","unstructured":"Woodruff, M. C. et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol. 21, 1506\u20131516 (2020).","journal-title":"Nat. Immunol."},{"key":"9034_CR55","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2666-5247(23)00012-5","volume":"4","author":"G Regev-Yochay","year":"2023","unstructured":"Regev-Yochay, G. et al. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe 4, e309\u2013e318 (2023).","journal-title":"Lancet Microbe"},{"key":"9034_CR56","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/v13112245","volume":"13","author":"M Krapi\u0107","year":"2021","unstructured":"Krapi\u0107, M., Kavazovi\u0107, I. & Wensveen, F. M. Immunological mechanisms of sickness behavior in viral infection. Viruses 13, 2245 (2021).","journal-title":"Viruses"},{"key":"9034_CR57","doi-asserted-by":"crossref","unstructured":"Zhou, B. et al. SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters1. Emerg. Microbes Infect. 12 (2023).","DOI":"10.1080\/22221751.2023.2245921"},{"key":"9034_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2220582","volume":"12","author":"C-J Li","year":"2023","unstructured":"Li, C.-J. & Chang, S.-C. SARS-CoV-2 spike S2-specific neutralizing antibodies. Emerg. Microbes Infect. 12, 2220582 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"9034_CR59","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1080\/21645515.2021.1934354","volume":"17","author":"GG Guerrero Manriquez","year":"2021","unstructured":"Guerrero Manriquez, G. G. & Tuero, I. Adjuvants: friends in vaccine formulations against infectious diseases. Hum. Vaccin Immunother. 17, 3539\u20133550 (2021).","journal-title":"Hum. Vaccin Immunother."},{"key":"9034_CR60","doi-asserted-by":"crossref","unstructured":"Dillard, J. A. et al. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus. Nat. Commun. 15 (2024).","DOI":"10.1038\/s41467-024-47450-x"},{"key":"9034_CR61","doi-asserted-by":"crossref","unstructured":"Ebenig, A. et al. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. Cell Rep. 40 (2022).","DOI":"10.1016\/j.celrep.2022.111214"},{"key":"9034_CR62","doi-asserted-by":"crossref","unstructured":"Kuo, S. M. Gender difference in bacteria endotoxin-induced inflammatory and anorexic responses. PLoS ONE 11 (2016).","DOI":"10.1371\/journal.pone.0162971"},{"key":"9034_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00840-0","volume":"9","author":"C Usai","year":"2024","unstructured":"Usai, C. et al. Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models. NPJ Vaccines 9, 48 (2024).","journal-title":"NPJ Vaccines"},{"key":"9034_CR64","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mcp.2012.01.002","volume":"26","author":"JG Dauner","year":"2012","unstructured":"Dauner, J. G. et al. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol. Cell Probes 26, 73\u201380 (2012).","journal-title":"Mol. Cell Probes"},{"key":"9034_CR65","doi-asserted-by":"publisher","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","volume":"25","author":"VM Corman","year":"2020","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 25, 2000045 (2020).","journal-title":"Eurosurveillance"},{"key":"9034_CR66","first-page":"1","volume":"12","author":"M Brustolin","year":"2021","unstructured":"Brustolin, M. et al. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerg. Microbes Infect. 12, 1\u201336 (2021).","journal-title":"Emerg. Microbes Infect."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09034-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:11:28Z","timestamp":1764180688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-09034-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9034"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-09034-3","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.I.U. is supported by institutional funding from Pharma Mar, HIPRA, Amassence, and Palobiofarma. The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1643"}}